INTRODUCTION
Asthma is a common, chronic disease affecting around 300 million individuals worldwide [1] . Treatment of asthma with inhaled corticosteroids (ICSs) is recommended by the Global Initiative for Asthma (GINA) [1] . It is very important that the ICS is correctly taken [2] ; however, poor compliance and incorrect handling of inhalers are frequent among people with asthma [3] . Patient preferences and opinions of the inhaler properties play a pivotal role for treatment outcomes. How patients perceive the handling of the device is often neglected [4] . Faulty technique can sabotage even the best of treatment plans for asthma [5] . Most patients cannot use the pressurized metered dose inhaler correctly [6, 7] , and while dry powder inhalers (DPIs) are easier to use, patients also make mistakes when using these [8] . The Novolizer Ò (Meda, Sweden) inhaler device was specifically designed to overcome many of the disadvantages associated with other DPIs. Compared to other DPIs, the Novolizer has a low-medium intrinsic resistance, and still patients need only to generate an inspiratory flow rate of 35 L/min for optimal drug delivery [9] . The dynamic resistance of the Novolizer is 5.5-times lower than that of the Turbuhaler Ò (AstraZeneca) and patients achieve significantly higher peak inspiratory flow rates and better inhalation performance with the Novolizer [10, 11] . The Novopulmon Novolizer deposits significantly more budesonide into the lungs than the Turbuhaler, more reliably, and with less variability of lung deposition [12] [13] [14] . In addition, the Novolizer is simple to use and simple to refill, rendering it forgiving of poor patient technique [15] . The optical, acoustic, and sensory feedback systems guide patients through a successful inhalation maneuver and provide confidence that the drug has reached the lungs [15] [16] [17] .
The present study was performed in patients who were prescribed a switch of DPI in standard clinical practice by their physician. The main objective of this study was to determine the proportion of patients preferring the new inhaler upon switching device as well as after using new inhaler device. Secondary objectives were to determine the reasons for switching and to survey the patients' positive/negative opinions of different properties and functions of their ICS inhaler.
METHODS

Patients
Male and female asthma patients of C6 years of age were included. To be eligible for the study, patients had to be receiving maintenance treatment with an ICS DPI (Step 2 according to GINA guidelines) [1] Answers to further four questions regarding functions of the inhaler and training on inhalers were presented as summary statistics.
All statistical analyses were performed using SAS Ò (Version 9.3, SAS Institute Inc., Cary, NC, USA).
Safety
Suspected adverse drug reactions (ADRs) were assessed and documented in the case report form (CRF). The physician was required to document whether a reasonable causal relationship with the drug (yes/no) could be assigned for each adverse reaction reported.
RESULTS
Patient Disposition
The planned sample size of 323 patients was not reached at study termination after 19 months. After termination, a total of 280 subjects were recruited and of these 17 did not return for the final visit. Full patient disposition is provided in Table 1 .
Since most patients switched from an ICS DPI to the Novopulmon Novolizer inhaler (98%), a modified intent-to-treat (ITT) data set of these patients was selected for the efficacy evaluation. Very few patients switched to Diskus Ò (GlaxoSmithKline); 3 patients or Easyhaler Ò (Orion); 2 patients and thus these were not included in the efficacy analysis (Table 1) . To allow for comparison between the major brands, further 11 patients that had not used Diskus, Easyhaler, or Turbuhaler as the ITT intent-to-treat a Excluded from modified ITT (n = 11) patients who had not received either Turbuhaler, Diskus, or Easyhaler as the old inhaler treatment old ICS DPI were also excluded from the modified ITT efficacy analysis (n = 242).
Patient Demographics
The age and sex distribution of patients included in the analysis is shown in Tables 2  and 3 for the modified ITT efficacy analysis data set. The age of the participating patients ranged between 6 and 85 years.
Previous Inhaler Use
Turbuhaler, Diskus, and Easyhaler were the most commonly previously used DPIs for all age groups (Table 3) . Nine patients had used other inhalators (including spray devices), of which four patients had previously used the DPI groups, while handling problems were also frequently reported among those aged 6-12 years (Fig. 1) . Insufficient asthma control appeared particularly pertinent to patients' desire to switch from the Easyhaler for all the age groups assessed. The main reasons given were not based on pre-defined definitions.
Inhaler Properties For all properties and functions, more outcomes are favorable for the Novopulmon Novolizer as compared to the previously used inhaler (Fig. 2) . Compared with previously used inhalers, patients switched to the Novopulmon Novolizer found it easier to load, easier to inhale through, and easier to tell if they had inhaled the medicine.
The patient's overall opinion of the Novopulmon Novolizer was also higher than that of previously used devices (OR 7.74; 95% CI 5.27-11.4; P\0.0001). Compared with previously used inhalers, patients switched to Novopulmon Novolizer also found it easier to use, easy to learn how to use and easy to know how much drug was left in the inhaler. Patients preferred the shape and size of the Novopulmon Novolizer compared with their previously used DPI and found it easier to carry with them (Fig. 2) Around one-fifth to one-half of all patients had received repeat information on how to use the old inhaler device prior to switching (18% to 53% across the age groups). Repeat demonstration of inhaler technique by the patient using the old device occurred more frequently among younger patients (58% of 6-12 year olds and 56% of 13-17 year olds) than among adults (18%).
Patients judged that the most valuable functions for knowing if the medicine was taken were 'hearing a sound,' 'change of color,' and 'taste sensation.'
Safety
Three ADRs were reported in the study by patients that switched to the new inhaler Novopulmon Novolizer, which led to treatment discontinuation; these included teeth discoloration, erythema, and cough.
DISCUSSION
This study was performed in patients who were prescribed a switch of DPI in standard clinical practice by their physician, and was designed to collect data on how patients evaluate a new inhaler when switching from a previously used inhaler. The key finding of this study is that the vast majority of patients across the age groups preferred to continue to use the new Novopulmon Novolizer at study end. A further finding of the study is that patients rated the influence on compliance and achievement of treatment goals for asthma [20, 21] . Regrettably, poor compliance and incorrect handling of inhalers is common among people with asthma [3, 22] . When technique is markedly flawed, suboptimal outcomes typically result, such as poor asthma control and increased frequency of emergency department visits [1, 5, 6, [22] [23] [24] . The Novolizer is a technically advanced DPI, which comprises a number of features that should improve compliance, safety, and efficacy. We have demonstrated that the Novolizer is associated with high patient preference, and it is suitable for patients with asthma regardless of severity [25] .
The ease of handling of the Novopulmon Novolizer device with audible, visual, and sensory feedback mechanisms are attributes that contribute to the higher degree of patient preference. These attributes combined with medium airflow resistance makes the device suitable for use especially in very young patients able to use a DPI and for elderly patients who may not be capable of generating sufficient inhalation flow [16] . The Novolizer device has shown lower variability in lung deposition in vivo compared with the Turbuhaler device [14] . Handling problems with the previously used device were more frequently reported among the younger age group (aged 6-12 years) as the reason for switching. Future studies should explore the clinicians' and patient/guardians' views on switching from metered dose inhalers to DPIs in young patients suitable for DPIs.
Strength of this study is that it is a real-life clinical situation comparing previous inhaler use with the Novopulmon Novolizer.
Randomized controlled trials usually exclude patients with suboptimal inhaler technique [3, 22] . Other published studies, systematic reviews, and guidelines have shown that patients do not get the full value of their inhaled medications because they use their inhaler incorrectly. Errors are made in inhalation technique and handling of the inhaler devices [6, 8, 22, 26] .
The findings of our study are in-line with those of Perpiñá Tordera et al. [27] who investigated patient satisfaction and preference for three different inhalers, Novolizer, Turbuhaler, and Accuhaler after one week of use. In the younger age group below 16 years, the preferred inhaler was Novolizer (60%) while Turbuhaler and Accuhaler were only preferred by 20% of patients in each case (P = 0.04). However, for the overall group no significant difference for preference was seen between the inhalers. In an earlier 4-week observational study, Novolizer was rated as better than previously used inhalers by 83% of patients [28] . In a further 4-week observational study, an improvement in compliance due to the control mechanisms of the Novopulmon Novolizer was observed in 80% of the 3057 patients [29] . 
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